US · Healthcare · Diagnostics & Research
EPS came in at 0.52 against a street estimate of 0.07 — a beat of 642.9%.
Analysts rate CareDx Inc a buy (5 buy, 2 hold, 0 sell out of 7) with an average price target of $93.50.
CONFIDENT CareDx delivered strong Q3 growth, raised 2026 revenue and EBITDA guidance, expanded transplant adoption, and advanced NavDx, AlloHeme, and HistoMap. Q3 FY26 Management cited continued adoption of kidney, lung, and heart surveillance protocols, with 21 centers live on Epic Aura. Analysts focused on transplant volume, NavDx pricing, collections, margins, and pipeline launches. Management emphasized sustained utilization, pricing upside, protocol expansion, and operational execution. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.31% |
| State Street Corp | 4.77% |
| Vanguard Capital Management, LLC | 4.25% |
| Deerfield Management Co | 3.86% |
| ARK Investment Management LLC | 3.78% |
| Boston Partners Global Investors, Inc | 3.75% |
| BAMCO Inc | 3.74% |
| Gagnon Securities LLC | 3.42% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $139.362 million, up from $100.055 million in the third quarter of 2025. • Nine-month 2026 revenue | 2026-10-29 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue was $139 million, up 39% year over year from $100 million. • GAAP net income was $19 million, compared with $2 mi | 2026-10-29 |
| Quarterly report · Q2 2026 CAREDX, INC. - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $373.6 million (June 30, 2026) vs. $65.4 million (Dec 31, 2025) — increase of | 2026-07-30 |
| Results announced · Q3 2026 CAREDX, INC. – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total Q2 2026 revenue: $132 million, up 52% year-over-year (vs. $87 million in Q2 2025) • | 2026-07-30 |
| Acquisition completed · Q2 2026 CAREDX, INC. – FORM 8-K SUMMARY (June 30 – July 1, 2026) --- HEADLINE NUMBERS • Eurobio Sale Completed (June 30, 2026): CareDx sold CareDx AB (Swed | 2026-07-07 |
| Board / officer change · Q2 2026 CAREDX, INC. – FORM 8-K SUMMARY (JUNE 11, 2026) HEADLINE NUMBERS • Annual Meeting held June 11, 2026 with 48,142,732 shares present (93% of outstand | 2026-06-15 |
| Quarterly report · Q1 2026 CAREDX, INC. – Q1 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Total Revenue Q1 2026: $117.7 million vs. $84.7 million Q1 2025 (+38.9% year-over-year) | 2026-04-28 |
| Results announced · Q2 2026 CAREDX, INC. - Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Total Revenue: $117.7 million (Q1 2026), up 39% year-over-year from $84.7 million (Q1 20 | 2026-04-28 |
Readable in the app.
| Announcement | Date |
|---|---|
| Completed acquisition of Naveris and sale of CareDx AB subsidiary CareDx completed two major transactions in late June/early July 2026. First, it sold its Swedish subsidiary CareDx AB and kitted laboratory products business to Eurobio Scientific for $171.7 | 2026-07-07 |
| Company enters into merger agreement and authorizes $100M stock repurchase program CareDx announced Q1 2026 financial results on April 28, 2026, along with two major corporate actions. First, the company entered into a merger agreement to acquire Naveris, Inc., though spec | 2026-04-28 |
| Entry into Purchase Agreement for transaction On April 15, 2026, CareDx, Inc. announced entry into a Purchase Agreement with Eurobio Scientific S.A. The company also disclosed preliminary unaudited financial results for Q1 2026 (quarter | 2026-04-16 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for CareDx Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.